WO2016209057A3 - 신경전구세포의 분비단백체를 유효성분으로 포함하는 허혈성 질환 또는 신경염증 질환 치료용 조성물 - Google Patents

신경전구세포의 분비단백체를 유효성분으로 포함하는 허혈성 질환 또는 신경염증 질환 치료용 조성물 Download PDF

Info

Publication number
WO2016209057A3
WO2016209057A3 PCT/KR2016/006848 KR2016006848W WO2016209057A3 WO 2016209057 A3 WO2016209057 A3 WO 2016209057A3 KR 2016006848 W KR2016006848 W KR 2016006848W WO 2016209057 A3 WO2016209057 A3 WO 2016209057A3
Authority
WO
WIPO (PCT)
Prior art keywords
secretome
active ingredient
composition
ischemic diseases
progenitor cells
Prior art date
Application number
PCT/KR2016/006848
Other languages
English (en)
French (fr)
Other versions
WO2016209057A2 (ko
Inventor
김동욱
김한수
Original Assignee
연세대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 연세대학교 산학협력단 filed Critical 연세대학교 산학협력단
Priority to AU2016283612A priority Critical patent/AU2016283612B2/en
Priority to EP16814770.0A priority patent/EP3315133B1/en
Priority to CN201680037482.5A priority patent/CN107921068A/zh
Priority to CA2990807A priority patent/CA2990807C/en
Priority to ES16814770T priority patent/ES2815537T3/es
Priority to JP2017566411A priority patent/JP2018518503A/ja
Priority to US15/739,958 priority patent/US10688135B2/en
Publication of WO2016209057A2 publication Critical patent/WO2016209057A2/ko
Publication of WO2016209057A3 publication Critical patent/WO2016209057A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)

Abstract

본 발명은 신경전구세포(Neural precursor cell; NPC)의 분비단백체를 유효성분으로 포함하는 허혈성 질환 또는 신경염증 질환 치료용 조성물을 제공한다. 본 발명의 신경전구세포의 분비단백체는 항염증, 신생혈관재생, 내재적줄기세포 가동 및 증식 등 역할로, 허혈성 손상 부위를 감소시킬 뿐만 아니라, 신경기능을 회복시키는바 허혈성 질환과 염증으로 인한 신경 손상 질환과 같은 퇴행성 신경계 질환의 치료제로서 이용될 수 있다. 특히 본 발명의 신경전구세포의 분비단백체는 다회 투여하는 경우 행동개선 효과가 매우 뛰어나다.
PCT/KR2016/006848 2015-06-26 2016-06-27 신경전구세포의 분비단백체를 유효성분으로 포함하는 허혈성 질환 또는 신경염증 질환 치료용 조성물 WO2016209057A2 (ko)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2016283612A AU2016283612B2 (en) 2015-06-26 2016-06-27 Composition for treating ischemic diseases or neuroinflammatory diseases, comprising secretome of neural precursor cells as active ingredient
EP16814770.0A EP3315133B1 (en) 2015-06-26 2016-06-27 Composition for treating ischemic diseases or neurogenic inflammatory disorders, containing secretome of neural progenitor cells as active ingredient
CN201680037482.5A CN107921068A (zh) 2015-06-26 2016-06-27 包含神经前体细胞的分泌蛋白质组作为有效成分的用于治疗缺血性疾病或神经炎症疾病的组合物
CA2990807A CA2990807C (en) 2015-06-26 2016-06-27 Composition for treating ischemic diseases or neuroinflammatory diseases, comprising secretome of neural precursor cells as active ingredient
ES16814770T ES2815537T3 (es) 2015-06-26 2016-06-27 Composición para el tratamiento de enfermedades isquémicas o trastornos inflamatorios neurogénicos, que contienen el secretoma de células progenitoras neurales como ingrediente activo
JP2017566411A JP2018518503A (ja) 2015-06-26 2016-06-27 神経前駆細胞の分泌タンパク質を有効成分として含む虚血性疾患または神経炎症疾患の治療用組成物
US15/739,958 US10688135B2 (en) 2015-06-26 2016-06-27 Composition for treating ischemic diseases or neuroinflammatory diseases, comprising secretome of neural precursor cells as active ingredient

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2015-0091378 2015-06-26
KR20150091378 2015-06-26

Publications (2)

Publication Number Publication Date
WO2016209057A2 WO2016209057A2 (ko) 2016-12-29
WO2016209057A3 true WO2016209057A3 (ko) 2017-02-16

Family

ID=57585690

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/006848 WO2016209057A2 (ko) 2015-06-26 2016-06-27 신경전구세포의 분비단백체를 유효성분으로 포함하는 허혈성 질환 또는 신경염증 질환 치료용 조성물

Country Status (9)

Country Link
US (1) US10688135B2 (ko)
EP (1) EP3315133B1 (ko)
JP (1) JP2018518503A (ko)
KR (1) KR101830945B1 (ko)
CN (1) CN107921068A (ko)
AU (1) AU2016283612B2 (ko)
CA (1) CA2990807C (ko)
ES (1) ES2815537T3 (ko)
WO (1) WO2016209057A2 (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210187040A1 (en) * 2017-09-01 2021-06-24 Orig3N, Inc. Ipsc-derived secretome compositions, and related systems and methods
CN107858331B (zh) * 2017-11-02 2021-01-15 北京全式金生物技术有限公司 一种诱导人多能性干细胞分化为脊髓运动神经前体细胞的方法
WO2019144102A1 (en) * 2018-01-22 2019-07-25 Angiocrine Bioscience, Inc. Compositions and methods for treatment of spinal cord injury
WO2020153687A1 (ko) * 2019-01-22 2020-07-30 고려대학교 산학협력단 직접 세포전환을 기반으로한 신경줄기세포의 성상교세포로의 분화방법
US11357823B2 (en) * 2019-08-30 2022-06-14 Suzhou Yabao Pharmaceutical R&D Co., Ltd Method for treating cerebral stroke
KR102526196B1 (ko) * 2019-11-19 2023-04-27 아주대학교산학협력단 Cotl1을 유효성분으로 포함하는 인지기능장애 진단, 예방 또는 치료용 조성물
WO2021101257A1 (ko) * 2019-11-19 2021-05-27 아주대학교산학협력단 Cotl1을 유효성분으로 포함하는 인지기능장애 진단, 예방 또는 치료용 조성물
KR20220061403A (ko) * 2020-11-06 2022-05-13 (주) 에스바이오메딕스 다능성 줄기세포 유래 신경전구세포를 포함하는 퇴행성 뇌질환 치료용 약학적 조성물
CN113632765B (zh) * 2021-03-31 2023-01-03 中山大学中山眼科中心 视网膜新生血管疾病动物模型、构建方法及其应用
KR20230047936A (ko) * 2021-10-01 2023-04-10 주식회사 입셀 유도만능줄기세포 배양 배지 유래 성분을 포함하는 조성물 내지 이의 용도
CN114452376A (zh) * 2022-01-21 2022-05-10 上海市精神卫生中心（上海市心理咨询培训中心） 胰岛素样生长因子结合蛋白2在制备治疗神经脱髓鞘性疾病的药物中的应用
CA3189560A1 (en) * 2022-03-04 2023-09-04 Suzhou Yabao Pharmaceutical R&D Co., Ltd. Methods of treating a traumatic brain injury

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140071512A (ko) * 2011-01-12 2014-06-11 츠네오 키도 시험관 내 조건에서 희돌기아교-계통 세포로 분화하는 경향이 있는 포유류의 신경줄기세포 및／또는 신경선조세포의 순수 또는 농축 세포군을 수득하고 유지하는 세포배양방법
WO2015199499A1 (ko) * 2014-06-27 2015-12-30 연세대학교 산학협력단 신경전구세포 또는 이의 분비단백체를 유효성분으로 포함하는 허혈성 질환 또는 신경염증 질환 치료용 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8187875B2 (en) 2004-02-26 2012-05-29 Reliance Life Sciences Pvt. Ltd. Dopaminergic neurons derived from corneal limbus, methods of isolation and uses thereof
KR101399056B1 (ko) 2012-04-16 2014-05-27 연세대학교 산학협력단 줄기세포-유래 미세소포체를 유효성분으로 포함하는 신경질환 예방 또는 치료용 약제학적 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140071512A (ko) * 2011-01-12 2014-06-11 츠네오 키도 시험관 내 조건에서 희돌기아교-계통 세포로 분화하는 경향이 있는 포유류의 신경줄기세포 및／또는 신경선조세포의 순수 또는 농축 세포군을 수득하고 유지하는 세포배양방법
WO2015199499A1 (ko) * 2014-06-27 2015-12-30 연세대학교 산학협력단 신경전구세포 또는 이의 분비단백체를 유효성분으로 포함하는 허혈성 질환 또는 신경염증 질환 치료용 조성물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KIM, D. S. ET AL.: "Highly Pure and Expandable PSA-NCAM-positive Neural Precursors from Human ESC and iPSC-derived Neural Rosettes", PLOS ONE, vol. 7, no. 7, 2012, pages 1 - 12, XP055248737 *
KIM, H. S. ET AL.: "PSA-NCAM+ Neural Precursor Cells from Human Embryonic Stem Cells Promote Neural Tissue Integrity and Behavioral Performance in a Rat Stroke Model", STEM CELL REVIEWS AND REPORTS, vol. 10, no. 6, 2014, pages 761 - 771, XP055363875 *
LEE, D. R. ET AL.: "PSA-NCAM-negative Neural Crest Cells Emerging during Neural Induction of Pluripotent Stem Cells Cause Mesodermal Tumors and Unwanted Grafts", STEM CELL REPORTS, vol. 4, no. 5, 12 May 2015 (2015-05-12), pages 821 - 834, XP055363877 *

Also Published As

Publication number Publication date
US10688135B2 (en) 2020-06-23
ES2815537T3 (es) 2021-03-30
AU2016283612A1 (en) 2018-02-15
US20180228845A1 (en) 2018-08-16
EP3315133B1 (en) 2020-07-22
CN107921068A (zh) 2018-04-17
EP3315133A2 (en) 2018-05-02
CA2990807C (en) 2023-03-14
KR101830945B1 (ko) 2018-02-23
AU2016283612B2 (en) 2019-01-24
CA2990807A1 (en) 2016-12-29
KR20170001943A (ko) 2017-01-05
JP2018518503A (ja) 2018-07-12
EP3315133A4 (en) 2018-05-30
WO2016209057A2 (ko) 2016-12-29

Similar Documents

Publication Publication Date Title
WO2016209057A3 (ko) 신경전구세포의 분비단백체를 유효성분으로 포함하는 허혈성 질환 또는 신경염증 질환 치료용 조성물
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
MX2021009673A (es) Moduladores de ror-gamma.
PH12016501735B1 (en) Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same
WO2017098328A8 (en) Therapeutic inhibitory compounds
WO2018060732A3 (en) Compositions and methods for treating seizure disorders
WO2017075338A3 (en) Delivery of central nervous system targeting polynucleotides
EA033113B1 (ru) Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта
MX2018000419A (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor.
WO2010081091A3 (en) Therapeutic compositions for treatment of corneal disorders
MY199091A (en) Therapeutic compounds
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
EP3162372A4 (en) Composition for treating ischemic diseases or neurogenic inflammation, containing, as active ingredient, neural progenitor cells or secretome thereof
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
MY201535A (en) Therapeutic compounds
WO2018015818A8 (en) Therapeutic inhibitory compounds
MX2017006513A (es) Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor.
WO2015048188A8 (en) Modified fibroblast growth factors for the treatment of ocular disorders
WO2018229543A3 (en) Therapeutic inhibitory compounds
GB2537783A (en) Methods and compositions used in treating inflammatory and autoimmune diseases
PH12019501785A1 (en) Intranasal composition comprising betahistine
EP3659584A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISORDERS, CONTAINING HDL-APOM-S1P AS ACTIVE INGREDIENT
PH12018500682A1 (en) Oxa-diazaspiro compounds having activity against pain
EP3409130A4 (en) COMPOSITION FOR THE PREVENTION, TREATMENT OR TREATMENT OF NEUROLOGICAL DISEASES WITH NOVEL PEPTIDE FOR THE ACTIVATION OF ADIPONECTIN RECEPTORS AS AN ACTIVE SUBSTANCE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16814770

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2017566411

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2990807

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 15739958

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2016814770

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016283612

Country of ref document: AU

Date of ref document: 20160627

Kind code of ref document: A